Table 2.
Variables | Census survey (November 15–April 16) |
Visit 1 (April–May 18) |
Visit 2 (September–October 18) |
Visit 3 (April–May 19) |
Visit 4 (October–November 19) |
Visit 5 (October–November 20) |
Questionnaire data | ||||||
No participants interviewed | 9124 | 1394 | 2009 | 2017 | 2130 | 2074 |
Demographic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Socioeconomic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Occupational | ✓ | ✓ | ✓ | ✓ | ✓ | |
Behavioural | ✓ | ✓ | ✓ | ✓ | ✓ | |
Clinical | ✓ | ✓ | ✓ | ✓ | ✓ | |
Travel history | ✓ | ✓ | ✓ | |||
Laboratory data | ||||||
No blood samples collected* | 1082 | 1696 | 1578 | 1768 | 1677 | |
Malaria microscopy | ✓ | ✓ | ✓ | ✓ | ✓ | |
Malaria RDT | ✓ | ✓ | ✓ | ✓ | ||
Malaria PCR | ✓ | ✓ | ✓ | ✓ | ✓ | |
Duffy/DARC genotyping | ✓ | ✓ | ✓ | ✓ | ✓ | |
CYP2D6 genotyping | ✓ | ✓ | ✓ | ✓ | ✓ | |
SARS-CoV-2 antibodies | ✓ | |||||
Dengue antibodies | ✓ | ✓ | ||||
Malaria parasite sequencing and phenotyping† | ✓ | ✓ | ✓ | ✓ | ✓ |
✓denotes that the measurement has been made at the noted study visit.
*Finger-prick capillary blood samples collected for malaria diagnosis were used for human genetic and SARS-CoV-2 studies.
†Venous blood samples were collected from consenting study participants with laboratory-confirmed malaria and leucocyte depleted for whole-genome sequencing and ex-vivo phenotypic assays.
RDT, rapid diagnostic test.